Maintenance bioimmunotherapy for epithelial ovarian cancer
Editorial Group: Cochrane Gynaecological Cancer Group
Published Online: 11 MAY 2011
Assessed as up-to-date: 11 APR 2011
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
How to Cite
Mei L, Chen H, Chen F, Feng D, Fang F. Maintenance bioimmunotherapy for epithelial ovarian cancer (Protocol). Cochrane Database of Systematic Reviews 2011, Issue 5. Art. No.: CD009137. DOI: 10.1002/14651858.CD009137.
- Publication Status: Edited (no change to conclusions)
- Published Online: 11 MAY 2011
This is the protocol for a review and there is no abstract. The objectives are as follows:
To assess the effectiveness and toxicity of maintenance bioimmunotherapy available for epithelial ovarian cancer and to evaluate the impact on the quality of life (QoL) of maintenance bioimmunotherapy. We will update this review once new treatments are available, but the first step is to evaluate interferon-alpha, matrix metalloprotease inhibitor, monoclonal antibodies, and some radioimmunotherapies, which have been studied by phase trials.